Incorporating hematopoietic stem-cell transplantation after second-line carfilzomib-lenalidomide-dexamethasone (KRd)

Therapeutic Advances in Hematology
Ja Min Byunand the Korean Multiple Myeloma Working Party (KMMWP)

Abstract

Traditionally believed to be an integral part of multiple myeloma (MM) treatment, the role of hematopoietic stem-cell transplantation (HSCT) is being challenged. As such, we sought to evaluate the impact of HSCT in the era of novel agents. A multicenter, retrospective, longitudinal cohort study was carried out between January 2016 and December 2018. A total of 55 patients who received VTD (bortezomib-thalidomide-dexamethasone) as first-line treatment and KRd (carfilzomib-lenalidomide-dexamethasone) as second-line treatment were analyzed for outcomes. The enrolled patients were divided into Group 1, defined as those who continued KRd treatment until progression (n = 41), versus Group 2, defined as those who underwent HSCT after a certain number of cycles of KRd (n = 14). Both groups showed a generally favorable response to KRd, with overall response rate (ORR) of 87.9% and clinical benefit rate of 92.8% after a median of seven cycles in Group 1, and ORR 92.8% and clinical benefit rate 100% after median of five cycles in Group 2. However, significantly poorer progression-free survival (PFS) (p = 0.004) was observed in Group 1 (median 12 months) compared with Group 2 (median not reached). Multivariate analyses identified HSCT afte...Continue Reading

References

May 9, 2003·The New England Journal of Medicine·J Anthony ChildUNKNOWN Medical Research Council Adult Leukaemia Working Party
Jan 24, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·John KorethEdwin P Alyea
Mar 24, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marco LadettoAntonio Palumbo
Apr 15, 2010·Social Work in Public Health·Dong Soo Kim
Jun 15, 2010·International Journal of Hematology·Jae Hoon LeeUNKNOWN Korean Multiple Myeloma Working Party
Feb 5, 2011·Blood·S Vincent RajkumarUNKNOWN International Myeloma Workshop Consensus Panel 1
Mar 16, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruno PaivaJesus F San Miguel
Oct 22, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Sergio GiraltSteven Devine
Nov 30, 2016·Leukemia & Lymphoma·Dimitrios C ZiogasMeletios A Dimopoulos
Apr 6, 2017·The New England Journal of Medicine·Michel AttalUNKNOWN IFM 2009 Study
Dec 12, 2018·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Patrick Alan Hagen, Patrick Stiff
Apr 10, 2019·Blood Cancer Journal·Rama Al HamedMohamad Mohty

❮ Previous
Next ❯

Citations

Jan 16, 2021·Annals of Hematology·Ji Hyun LeeUNKNOWN Korean multiple myeloma working party [KMMWP]

❮ Previous
Next ❯

Software Mentioned

SPSS® Statistics
Statistical Package for the Social Sciences

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.